Last updated: 11/07/2018 17:13:09
In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in Subjects with type 2 Diabetes Mellitus
Trial description: This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the bloodstream when it is given at the same dose 7 days apart, and the impact this medication has on various substances in the blood. Assessments include ECGs, vital signs, repeat blood sampling and monitoring of any side effects.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:
blood plasma levels of GSK716155
Timeframe: on days 2 & 9
Secondary outcomes:
blood plasma levels of GSK716155
Timeframe: on days 2 & 9
Interventions:
Enrollment:
60
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Jessica E. Matthews, Murray W. Stewart, Erika H. De Boever, Robert L. Dobbins, Rebecca J. Hodge, Susan E. Walker, M. Claire Holland, Mark A. Bush, for the Albiglutide Study Group . Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2008;93(12):4810-4817.
Medical condition
Diabetes Mellitus, Type 2
Product
albiglutide
Collaborators
Not applicable
Study date(s)
February 2006 to September 2006
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 70 years
Accepts healthy volunteers
No
- Subjects must have type 2 diabetes mellitus that has been diagnosed for at least three months.
- Must be taking either (1) no medication for their diabetes or (2) taking metformin, a sulfonylurea, or metformin and a sulfonylurea.
- Laboratory values that meet certain criteria (for example, total cholesterol > 240 mg/dL).
- Clinically significant hepatic enzyme elevation.
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects must have type 2 diabetes mellitus that has been diagnosed for at least three months.
- Must be taking either (1) no medication for their diabetes or (2) taking metformin, a sulfonylurea, or metformin and a sulfonylurea.
- Subjects must be willing to wash-out of these medications for 14 days prior to the start of the study.
- Subjects must have a BMII between 25 and 40 kg/m² and weigh at leas 50kg.
- Women must be of non-childbearing potential.
Exclusion criteria:
- Laboratory values that meet certain criteria (for example, total cholesterol > 240 mg/dL).
- Clinically significant hepatic enzyme elevation.
- Fasting plasma glucose greater than 240mg/dL.
- Positive test result for Hepatitis B surface antigen, positive Hepatitis C or HIV.
- Any major illness other than diabetes.
- Previous use of insulin as treatment for diabetes.
- Significant renal disease as defined by screening lab tests.
- History of drug or other allergy, which in the opinion of the investigator contradicts subject participation.
- Smoking or use of nicotine-containing products within the previous 6 months.
- History of alcohol or drug abuse.
- Unwilling to abstain from alcohol during the study.
- Unwilling to abstain from caffeine- or xanthine-containing products during the study.
- Use of St. John's Wort during the study.
- Has donated 500 nL or more blood within 56 days of dosing or plans to donate blood in the month following study participation.
- Previously received any GLP-1 mimetic that has moe than 70% sequence homology to GLP-1.
Trial location(s)
Location
GSK Investigational Site
Portland, Oregon, United States, 97239
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Orlando, Florida, United States, 32809
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Honolulu, Hawaii, United States, 96814-4224
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Miramar, Florida, United States, 33025
Status
Terminated/Withdrawn
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2006-25-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website